At the Capio Prostate Cancer Center, a new diagnostic process using prostate-specific antigen, Stockholm3, magnetic resonance imaging, and targeted biopsies has been implemented to improve prostate cancer testing and diagnosis in Stockholm, Sweden. This evidence concerns the gene KLK3 and prostate cancer.